CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.
S Cohen, S M Stemmer, G Zozulya...
https://pubmed.ncbi.nlm.nih.gov/21660967/Actively Recruiting
Led by Can-Fite BioPharma · Updated on 2025-04-29
471
Participants Needed
32
Research Sites
34 weeks
Total Duration
Researchers are studying advanced hepatocellular carcinoma HCC in patients who have Child-Pugh Class B7 cirrhosis and whose cancer has worsened after at least one prior treatment. This clinical trial aims to compare the safety and effectiveness of the drug namodenoson with a placebo in this group of patients. The trial is a Phase 3, multicenter, randomized, double-blind study designed to provide clear evidence on the benefits and risks of namodenoson for this condition. Participants will be randomly assigned to receive either namodenoson 25 mg or a matching placebo by mouth twice daily in 28-day cycles. Treatment continues until the disease progresses or side effects become unacceptable. Tumor imaging is performed every two cycles to monitor disease status. After stopping the study drug, patients will have a follow-up visit 28 days later, and those who agree will be monitored long-term for survival. If results allow, some patients may continue taking namodenoson openly beyond the blinded phase. During the study, participants will regularly visit the clinic for safety checks, laboratory tests, and tumor imaging. The main outcome measured is overall survival up to 60 months after randomization. Secondary outcomes include progression-free survival, objective response rate, and the nature of side effects. Pharmacokinetics of namodenoson will also be studied. Long-term survival data will be collected for those who consent to follow-up, ensuring thorough monitoring throughout the study period.
CONDITIONS
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Z
Zivit Harpaz
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Can-Fite BioPharma
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Namodenoson (A3 Adenosine Receptor Agonist) | Placebo |
|---|---|---|
| What it is | Namodenoson is an oral drug targeting the adenosine A3 receptor, designed as a selective agonist with anti-tumor and anti-inflammatory properties for advanced liver cancer. | Placebo tablets matching Namodenoson are given under identical conditions for comparison with the investigational drug. |
| Role in trial | Tested as the investigational therapy for potential survival improvement in advanced hepatocellular carcinoma with Child-Pugh B7 cirrhosis. | Serves as the comparator to measure clinical outcomes against Namodenoson under blinded, randomized conditions. |
| Primary use | Investigated for the treatment of advanced hepatocellular carcinoma in patients with Child-Pugh class B7 cirrhosis who have progressed after prior systemic therapy. | Given as a control to evaluate the effect of Namodenoson compared to no active anti-tumor therapy, reflecting lack of established standard therapy for this population. |
| How it is given or performed | Namodenoson is administered orally as tablets, in a blinded and randomized manner, alongside routine assessments for treatment-emergent adverse events and disease progression. | Placebo tablets are given orally under the same trial conditions and monitoring as Namodenoson, maintaining blinding and randomization. |
| Evidence status | Results for Namodenoson in this phase 3 trial are not yet established. Prior studies and a published randomized trial suggest potential activity in advanced HCC with Child-Pugh B, but evidence remains investigational. Further data from phase 3 will clarify survival and efficacy outcomes. | Outcomes reflect the natural course of advanced hepatocellular carcinoma with Child-Pugh B7 cirrhosis after prior systemic therapy, where no established effective therapy exists; placebo serves as reference for comparison. |
| Important limitations | Clinical benefits and safety in the highly selected population with Child-Pugh B7 cirrhosis are not yet confirmed. Prior trials have been limited by small sample sizes and short follow-up. Survival in this patient group is generally poor, and risks associated with liver dysfunction may limit tolerability and effectiveness. | Placebo-controlled design reflects absence of a proven active therapy for advanced HCC with Child-Pugh B7 cirrhosis. Results may not apply to patients with better liver function or to settings where new therapies become available. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Repeated 28-day cycles until disease progression or discontinuation
Participants receive oral doses of namodenoson or placebo twice daily in consecutive 28-day cycles until disease progression or unacceptable side effects occur. Tumor imaging is performed every two cycles, and participants are regularly evaluated for safety.
Visits every 2 cycles for tumor imaging and regular safety evaluations
Duration - Indefinite follow-up for survival after treatment ends
Participants return for a follow-up visit 28 days after the last dose of study drug. Those who discontinue treatment and consent are followed indefinitely for survival status.
1 visit 28 days post-treatment and long-term survival follow-up visits as consented
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
S Cohen, S M Stemmer, G Zozulya...
https://pubmed.ncbi.nlm.nih.gov/21660967/Salomon M Stemmer, Ofer Benjaminov, Gal Medalia...
https://pubmed.ncbi.nlm.nih.gov/23299770/S Bar-Yehuda, S M Stemmer, L Madi...
https://pubmed.ncbi.nlm.nih.gov/18636149/Salomon M Stemmer, Nebojsa S Manojlovic, Mihai Vasile Marinca...
https://pubmed.ncbi.nlm.nih.gov/33430312/Can-Fite BioPharma
Lead Sponsor